Identification of a novel compound heterozygous mutation of the CYP21A2 gene causing 21‑hydroxylase deficiency in a Chinese pedigree

Liu,Jia; Zhang,Xiujuan; Zhang,Haiqing; Fang,Li; Xu,Jin; Guan,Qingbo; Xu,Chao

doi:10.3892/mmr.2018.8391

Identification of a novel compound heterozygous mutation of the CYP21A2 gene causing 21‑hydroxylase deficiency in a Chinese pedigree

Authors:
- Jia Liu
- Xiujuan Zhang
- Haiqing Zhang
- Li Fang
- Jin Xu
- Qingbo Guan
- Chao Xu
View Affiliations

Affiliations: Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China, Shandong Clinical Medical Center of Endocrinology and Metabolism, Jinan, Shandong 250021, P.R. China
Published online on: January 8, 2018 https://doi.org/10.3892/mmr.2018.8391
Pages: 4265-4272
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

21‑Hydroxylase deficiency (21‑OHD) is the most common cause of congenital adrenal hyperplasia. Inherited in an autosomal recessive manner, 21‑OHD is caused by mutations in the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene. The present study was designed to investigate the genetic characteristics of one Chinese pedigree and to identify the genotype‑phenotype association, thereby facilitating the precise diagnosis of 21‑OHD at the molecular level. Members of a Chinese family with 21‑OHD were screened for mutations in the CYP21A2 gene. Clinical data and biochemical parameters, including androgen and derivatives, were collected. Complete DNA sequencing and multiplex ligation‑dependent probe amplification (MLPA) were utilized to analyze the genetic variations in the full‑length CYP21A2 gene. A C‑T transition located in exon 8 of the CYP21A2 gene, leading to the predicted amino acid residue change from Arg to Trp at codon 342, was identified in the mother and four sisters. Additionally, heterozygous deletion mutations of exons 1, 3, 4, 6 and 7 of paternal origin were detected in the four sisters by MLPA analysis. During the one‑year follow‑up, the four sisters exhibited symptom improvement following treatment with glucocorticoids, and the proband and one sister successfully conceived. The results of the present study demonstrated that novel compound heterozygous variations in the CYP21A2 gene may be causative agents of 21‑OHD, providing insights into the functions of this gene and a more comprehensive understanding of the disorder.

View Figures

View References

1	Bachelot A, Grouthier V, Courtillot C, Dulon J and Touraine P: Management of endocrine disease: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Update in management of adult patients and prenatal treatment. Eur J Endocrinol. 176:R167–R181. 2017. View Article : Google Scholar : PubMed/NCBI
2	Forest MG: Recent advances in the diagnosis and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod Update. 10:469–485. 2004. View Article : Google Scholar : PubMed/NCBI
3	Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, et al: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 95:4133–4160. 2010. View Article : Google Scholar : PubMed/NCBI
4	White PC, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B and Strominger JL: Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci USA. 82:pp. 1089–1093. 1985; View Article : Google Scholar : PubMed/NCBI
5	White PC, New MI and Dupont B: Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci USA. 83:pp. 5111–5115. 1986; View Article : Google Scholar : PubMed/NCBI
6	Bruque CD, Delea M, Fernández CS, Orza JV, Taboas M, Buzzalino N, Espeche LD, Solari A, Luccerini V, Alba L, et al: Structure-based activity prediction of CYP21A2 stability variants: A survey of available gene variations. Sci Rep. 6:390822016. View Article : Google Scholar : PubMed/NCBI
7	Lee HH: Mutational analysis of CYP21A2 gene and CYP21A1P pseudogene: Long-range PCR on genomic DNA. Methods Mol Biol. 1167:275–287. 2014. View Article : Google Scholar : PubMed/NCBI
8	Li C, Zhou X, Han W, Jiang X, Liu J, Fang L, Wang H, Guan Q, Gao L, Zhao J, et al: Identification of two novel mutations in SLC12A3 gene in two Chinese pedigrees with Gitelman syndrome and review of literature. Clin Endocrinol (Oxf). 83:985–993. 2015. View Article : Google Scholar : PubMed/NCBI
9	Menassa R, Tardy V, Despert F, Bouvattier-Morel C, Brossier JP, Cartigny M and Morel Y: p.H62L, a rare mutation of the CYP21 gene identified in two forms of 21-hydroxylase deficiency. J Clin Endocrinol Metab. 93:1901–1908. 2008. View Article : Google Scholar : PubMed/NCBI
10	Antonarakis SE: Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 11:1–3. 1998. View Article : Google Scholar : PubMed/NCBI
11	den Dunnen JT and Antonarakis SE: Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion. Hum Mutat. 15:7–12. 2000. View Article : Google Scholar : PubMed/NCBI
12	White PC: Congenital adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab. 15:17–41. 2001. View Article : Google Scholar : PubMed/NCBI
13	Bánlaki Z, Szabó JA, Szilágyi Á, Patócs A, Prohászka Z, Füst G and Doleschall M: Intraspecific evolution of human RCCX copy number variation traced by haplotypes of the CYP21A2 gene. Genome Biol Evol. 5:98–112. 2013. View Article : Google Scholar : PubMed/NCBI
14	Barbaro M, Soardi FC, Östberg LJ, Persson B, de Mello MP, Wedell A and Lajic S: In vitro functional studies of rare CYP21A2 mutations and establishment of an activity gradient for nonclassic mutations improve phenotype predictions in congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 82:37–44. 2015. View Article : Google Scholar : PubMed/NCBI
15	Yu Y, Wang J, Huang X, Wang Y, Yang P, Li J, Tsuei SH, Shen Y and Fu Q: Molecular characterization of 25 Chinese pedigrees with 21-hydroxylase deficiency. Genet Test Mol Biomarkers. 15:137–142. 2011. View Article : Google Scholar : PubMed/NCBI
16	Coeli FB, Soardi FC, Bernardi RD, de Araújo M, Paulino LC, Lau IF, Petroli RJ, de Lemos-Marini SH, Baptista MT, Guerra-Júnior G and de-Mello MP: Novel deletion alleles carrying CYP21A1P/A2 chimeric genes in Brazilian patients with 21-hydroxylase deficiency. BMC Med Genet. 11:1042010. View Article : Google Scholar : PubMed/NCBI
17	Concolino P, Mello E, Zuppi C and Capoluongo E: Molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency: An update of new CYP21A2 mutations. Clin Chem Lab Med. 48:1057–1062. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lee HH, Chao HT, Ng HT and Choo KB: Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia. J Med Genet. 33:371–375. 1996. View Article : Google Scholar : PubMed/NCBI
19	Concolino P, Mello E, Toscano V, Ameglio F, Zuppi C and Capulongo E: Multiplex ligation-dependent probe amplification (MLPA) assay for the detection of CYP21A2 gene deletions/duplications in congenital adrenal hyperplasia: First technical report. Clin Chim Acta. 402:164–170. 2009. View Article : Google Scholar : PubMed/NCBI
20	White PC, Vitek A, Dupont B and New MI: Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. Proc Natl Acad Sci USA. 85:pp. 4436–4440. 1988; View Article : Google Scholar : PubMed/NCBI
21	Parajes S, Quinterio C, Domínguez F and Loidi L: A simple and robust quantitative PCR assay to determine CYP21A2 gene dose in the diagnosis of 21-hydroxylase deficiency. Clin Chem. 53:1577–1584. 2007. View Article : Google Scholar : PubMed/NCBI
22	Lee HH, Lee YJ and Lin CY: PCR-based detection of the CYP21 deletion and TNXA/TNXB hybrid in the RCCX module. Genomics. 83:944–950. 2004. View Article : Google Scholar : PubMed/NCBI
23	Krone N, Reisch N, Idkowiak J, Dhir V, Ivison HE, Hughes BA, Rose IT, O'Neil DM, Vijzelaar R, Smith MJ, et al: Genotype-phenotype analysis in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. J Clin Endocrinol Metab. 97:E257–E267. 2012. View Article : Google Scholar : PubMed/NCBI
24	Concolino P, Mello E, Patrosso MC, Penco S and Zuppi C: p.H282N and p.Y191H: 2 novel CYP21A2 mutations in Italian congenital adrenal hyperplasia patients. Metabolism. 61:519–524. 2012. View Article : Google Scholar : PubMed/NCBI
25	Baumgartner-Parzer SM, Fischer G and Vierhapper H: Predisposition for de novo gene aberrations in the offspring of mothers with a duplicated CYP21A2 gene. J Clin Endocrinol Metab. 92:1164–1167. 2007. View Article : Google Scholar : PubMed/NCBI
26	Leccese A, Longo V, Dimatteo C, De Girolamo G, Trunzo R, D'Andrea G, Bafunno V, Margaglione M and Santacroce R: Lack of genotype-phenotype correlation in congenital adrenal hyperplasia due to a CYP21A2-like gene. Clin Chim Acta. 437:48–51. 2014. View Article : Google Scholar : PubMed/NCBI
27	Anastasovska V and Kocova M: Genotype-phenotype correlation in CAH patients with severe CYP21A2 point mutations in the Republic of Macedonia. J Pediatr Endocrinol Metab. 23:921–926. 2010. View Article : Google Scholar : PubMed/NCBI
28	New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D, Sun L, Zaidi M, Wilson RC and Yuen T: Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci USA. 110:pp. 2611–2616. 2013; View Article : Google Scholar : PubMed/NCBI
29	Janjanin N, Dumic M, Skrabic V, Kusec V, Grubic Z and Spehar Uroic A: Five patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency (one with associated neuroblastoma) discovered in three generations of one family. Horm Res. 67:111–116. 2007.PubMed/NCBI